US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1?1%, as determined by an FDA-approved test.

Read more:
US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer